Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
CAMZYOS (Bristol-Myers Squibb Australia Pty Ltd)
Product name
CAMZYOS
Date registered
Evaluation commenced
Decision date
Approval time
195 (255 working days)
Active ingredients
mavacamten
Registration type
NCE/NBE
Indication
CAMZYOS is indicated for the treatment of adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy.